B
Bull
Bull · 25%GHRS
$19.41
Precio del escenario
$27.940
-0.693 (-2.48%)Al cierre
Loading chart…
- High
- 28.610
- Open
- 28.610
- VWAP
- 28.12
- Vol
- 117.67K
- Mkt Cap
- 623.82M
- Low
- 27.820
- Amount
- 3.31M
- EV/EBITDA, TTM
- 0.00
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is focusing on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD). Its portfolio includes GH001, its proprietary inhalable mebufotenin product candidate and GH002, its proprietary intravenous mebufotenin product candidate. GH001 is delivered via a vaporization device produced by a third party, and the Company is developing a proprietary aerosol delivery device which is in clinical investigation in Europe. GH001 completed two Phase 1 clinical trials in healthy volunteers, a Phase 1/2 trial in TRD and two Phase 2a proof-of-concept trials. GH002 Completed a randomized, double-blind, placebo-controlled, dose-ranging clinical pharmacology trial of GH002 in healthy volunteers, and it is developing GH002 within its focus area of psychiatric and neurological disorders.
AI analysis of GH Research PLC (GHRS)
buyGH Research PLC is a good buy right now due to its strong upside potential and solid analyst ratings. The current price is $27.94, with a price target from Wells Fargo of $44, indicating a potential upside of 56%. Additionally, the stock has shown impressive year-to-date growth of 111.03%, reflecting strong market interest despite recent volatility.
Métricas de valoración
The current forward P/E ratio for GH Research PLC (GHRS) is 0.00, compared to its 5-year average forward P/E of -18.18.
Alphio AI Price Scenarios for GHRS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding GHRS
Cronología de eventos
Noticias
6.007-27stocktwitsWells Fargo Initiates Positive Ratings on Biotech Firms
8.507-23NASDAQ.COMEli Lilly Acquires AtaiBeckley to Expand Behavioral Health Pipeline
8.507-23FoolEli Lilly Acquires Atai Beckley to Enter Psychedelic Market
8.507-20stocktwitsATAI Stock Hits Record Single-Day Gain Amid Downgrades
8.507-19NewsfilterEli Lilly Acquires AtaiBeckley, Advancing Psychedelic Drug Market
GHRS FAQ — answered by Alphio AI
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is focusing on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD). Its portfolio includes GH001, its proprietary inhalable mebufotenin product candidate and GH002, its proprietary intravenous mebufotenin product candidate. GH001 is delivered via a vaporization device produced by a third party, and the Company is developing a proprietary aerosol delivery device which is in clinical investigation in Europe. GH001 completed two Phase 1 clinical trials in healthy volunteers, a Phase 1/2 trial in TRD and two Phase 2a proof-of-concept trials. GH002 Completed a randomized, double-blind, placebo-controlled, dose-ranging clinical pharmacology trial of GH002 in healthy volunteers, and it is developing GH002 within its focus area of psychiatric and neurological disorders. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
GH Research PLC is a good buy right now due to its strong upside potential and solid analyst ratings. The current price is $27.94, with a price target from Wells Fargo of $44, indicating a potential upside of 56%. Additionally, the stock has shown impressive year-to-date growth of 111.03%, reflecting strong market interest despite recent volatility.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.